KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) Dent R, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Clinical performance of Immunoscore (R) in early colon cancer in the Asian population (2020) Galon J, Kawakami Y, Torigoe T, Wang Y, Patel PS, Vora H, Mlecnik B, et al. Conference contribution Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Conference contribution Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors (2020) Zhou JG, Ma H, Gaipl U Conference contribution Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. Conference contribution Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. Conference contribution Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al. Conference contribution